GlassScriptPhysician profile
Michael Joseph Gardner
NPI 1184616237
$14,075.84
in general payments reported to CMS, 2019-2025
58 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,110 · 2020: $2,458 · 2021: $3,619 · 2022: $3,244 · 2023: $1,645.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,239 · Travel and Lodging: $312 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,238.95 |
| Travel and Lodging | $312.17 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,630.42 | 2019-2023 | Rybelsus, Ozempic, Saxenda |
| Janssen Pharmaceuticals, INC | $1,281.41 | 2019-2023 | Spravato |
| Pfizer INC. | $1,084.49 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $981.79 | 2019-2023 | Jardiance |
| Glaxosmithkline, LLC. | $933.91 | 2019-2023 | Trelegy Ellipta, Shingrix |
| Abbvie INC. | $837.50 | 2019-2023 | |
| Astellas Pharma US INC | $513.22 | 2019-2023 | Myrbetriq |
| Merck Sharp & Dohme LLC | $456.13 | 2019-2023 | Steglatro, Belsomra |
| Lilly USA, LLC | $391.70 | 2019-2023 | Jardiance, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $360.89 | 2019-2023 | Farxiga |
| Amgen INC. | $356.91 | 2019-2023 | Otezla, Repatha |
| Boston Scientific Corporation | $350.22 | 2023 | S-Icd System Magnet |
| Amarin Pharma, INC. | $345.93 | 2019-2022 | |
| Gilead Sciences, INC. | $291.35 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $288.93 | 2019-2021 |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Gardner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.